Correlation Between Tempest Therapeutics and THC Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Tempest Therapeutics and THC Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Tempest Therapeutics and THC Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Tempest Therapeutics and THC Therapeutics, you can compare the effects of market volatilities on Tempest Therapeutics and THC Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Tempest Therapeutics with a short position of THC Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Tempest Therapeutics and THC Therapeutics.

Diversification Opportunities for Tempest Therapeutics and THC Therapeutics

0.35
  Correlation Coefficient

Weak diversification

The 3 months correlation between Tempest and THC is 0.35. Overlapping area represents the amount of risk that can be diversified away by holding Tempest Therapeutics and THC Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on THC Therapeutics and Tempest Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Tempest Therapeutics are associated (or correlated) with THC Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of THC Therapeutics has no effect on the direction of Tempest Therapeutics i.e., Tempest Therapeutics and THC Therapeutics go up and down completely randomly.

Pair Corralation between Tempest Therapeutics and THC Therapeutics

Given the investment horizon of 90 days Tempest Therapeutics is expected to under-perform the THC Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Tempest Therapeutics is 36.14 times less risky than THC Therapeutics. The stock trades about -0.13 of its potential returns per unit of risk. The THC Therapeutics is currently generating about 0.19 of returns per unit of risk over similar time horizon. If you would invest  0.04  in THC Therapeutics on August 29, 2024 and sell it today you would earn a total of  0.01  from holding THC Therapeutics or generate 25.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Tempest Therapeutics  vs.  THC Therapeutics

 Performance 
       Timeline  
Tempest Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Tempest Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
THC Therapeutics 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in THC Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain fundamental indicators, THC Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Tempest Therapeutics and THC Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Tempest Therapeutics and THC Therapeutics

The main advantage of trading using opposite Tempest Therapeutics and THC Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Tempest Therapeutics position performs unexpectedly, THC Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in THC Therapeutics will offset losses from the drop in THC Therapeutics' long position.
The idea behind Tempest Therapeutics and THC Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Other Complementary Tools

Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance